Join us on our journey of discovery

We’ve researched far and wide to collect the results for ODYSSEY OUTCOMES, a cardiovascular outcomes trial with alirocumab (a PCSK9 inhibitor).
The story Play video

Discover results from the ODYSSEY OUTCOMES trial conducted in post-acute coronary syndrome (ACS) patients testing


View alirocumab dose titration and the ODYSSEY OUTCOMES treat-to-target approach


Learn about primary MACE and additional CV endpoints in the overall population


Learn about the results on MACE in high risk patients (baseline LDL-C 100 mg/dL)


ACS=acute coronary syndrome; LDL-C low-density lipoprotein cholesterol; MACE=major adverse cardiovascular events; PCSK9=proprotein convertase subtilisin/kexin type 9.

Adverse events should be reported.

Reporting forms and information can be found at

Adverse events should also be reported to Sanofi on 0800 090 2314 or

See full prescribing information

Copyright © Sanofi and Regeneron Pharmaceuticals, Inc. 2020. All rights reserved.

Sanofi Copyright Reserved

ZYX-112233-20190102 Last Updated: January 2, 2019